GlaxoSmithKline (NYSE:GSK) touted new data today from a long-term study of its biologic treatment for patients with severe eosinophilic asthma.
One-third of patients treated with mepolizumab experienced no exacerbations, GSK reported – down from an average of two exacerbations each year at the start of the study.
Get the full story at our sister site, Drug Delivery News.
The post GlaxoSmithKline touts long-term study of biologic treatment for severe eosinophilic asthma appeared first on MassDevice.